Risk of cancer in liver transplant recipients: A look into the mirror

Liver Transplantation

Volumn 14, Issue 11, 2008, Pages 1561-1563

  Buell, Joseph F ^a,b   Brock, Guy N ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLON CANCER; DNA DAMAGE; DRUG EFFICACY; EDITORIAL; GRAFT RECIPIENT; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; LIP CANCER; LIVER CANCER; LIVER TRANSPLANTATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; COHORT STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER DISEASES; LIVER TRANSPLANTATION; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 57849106386     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21634     Document Type: Editorial

References (34)

1. Penn I. Cancers In renal transplant recipients. Adv Ren Replace Ther 2000;7:147-156.
2. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000;23:101-113.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998:147-148.
4. Diehl V, Hauch PM, Harris NL. Hodgkin's Disease. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Willkins; 2001:2339-2387.
5. Yarchoan R, Little RF. Immunosuppression-related malignancies. In: DeVita VT Jr. Hellman S, Rosenberg SA. eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:2575-2996.
6. Taylor L, Hughes RA, McPherson F, The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol 2004; 11:141.
7. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-S264.
8. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76:1289-1293.
9. Bustami RT, Ojo AO, Wolfe RA. Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87-93.
10. Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Schwarzmann F, et al. EBV-associated neoplasms: alternative pathogenetic pathways. Med Hypotheses 2004;62: 387-391.
11. Cao S, Cox K, Esquivel CO, Berquist W, Concepcion W, Ojogho O, et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation 1998;66:851-856.
12. Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol 2000; 79:220-224.
13. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997;64:669-673.
14. Mistrikova J, Mrmusova M, Durmanova V, Rajcani J. Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). Viral Immunol 1999;12:237-247.
15. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003:76:597-602.
16. Sakai M, Miyake H, Tashiro S, Okumura Y, Kido H. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells. J Med Invest 2004; 51:63-69.
17. Kalas W, Matuszyk J, Ziolo E, Strzadala. L. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. Anticancer Res 2003;23:1613-1617.
18. Villeneuve PJ, Schaubel DE., Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer Incidence among Canadian kidney transplant recipients. Am J Transplant 2007;7:941-948.
19. Jiang Y, Villeneuve PJ, Fenton SS, et al. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008; 14:1588-1597.
20. Adaml J, Gäbel H, Lindelöf K, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221-1227.
21. Chapman JR, Webster AC. Cancer after renal transplantation: the next challenge. Am J Transplant 2004;4:841-842.
22. Jain AB, Yee LD, Nalesnik MA, Youk A. Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphold malignancies after liver transplantation under tacrolimus using surveillance end result data. Transplantation 1998; 66:1193-1200.
23. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
24. Hanaway MJ, Trofe J, Buell JF, Lo A, Alloway RR, Beebe T, et al. Colon cancer risk in liver transplant recipients: the Israel Penn International Transplant Tumor Registry Experience. Am J Transplant 2001;11:264.
25. Husted TL, Hanaway MJ, Beebe TM, Trofe J, Gross TG, Woodle ES, Buell JF, et al. Pre-existing colon carcinoma in solid organ transplant recipients. (1472) Am J Transplant 2003;3:530.
26. Papaconstantinou HT, Skalow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, et al. Characteristics and survival of solid organ transplant patients developing de novo color. and rectal cancer. Dis Colon Rectum 2004;47:1898-1903.
27. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989; 14:119-123.
28. Port F. Standardized incidence ratio: the rate of de novo malignancies by site and transplanted organ compared to population-based controls. Presented at the 3rd Annual American Society of Transplant Surgeons (ASTS) Winter Symposium, "Tumors and Transplantation." Miami Beach, FL, January 24-26, 2003. Arlington, VA: ASTS.
29. Yu J, Page T, Connor JD, Connor JD, Yu AL. Induction of erythroid differentiation in K562 cells by inhibitors of Inosine monophosphate dehydrogenase. Cancer Res 1989; 49:5555-5560.
30. Carter SB, Franklin TJ, Jones TJ, Leonard BJ, Mills SD, Turner RW, Turner WB. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969;223: 848-850.
31. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives Cancer Res 1976;36:2923-2927.
32. Engl T, Markarevic J, Relja B, Natsheh I, Mülller I, Beecken. WD, et al. Mycophenolate mofetil modulates adhesion receptors of the beta I integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005: 5:1471-1482.
33. Kahan BD, Yakupoglu VK, Schoenberg L, Knight RJ, Katz SM, Lai D, VanBuren CT. Low incidence of malignancy among sirolimus-cyclosporine treated transplant recipients. Am J Transplant 2004;3(suppl 5):187.
34. Trotter JF. Strolimus in liver transplantation. Transplant Proc 2003;35(3 suppl):193S-200S.